AMROZ PHARM LIMITED

Company Registration Number:
11288434 (England and Wales)

Unaudited statutory accounts for the year ended 30 April 2025

Period of accounts

Start date: 01 May 2024

End date: 30 April 2025

AMROZ PHARM LIMITED

Contents of the Financial Statements

for the Period Ended 30 April 2025

Company Information - 3
Report of the Directors - 4
Profit and Loss Account - 5
Balance sheet - 6
Additional notes - 8
Balance sheet notes - 11

AMROZ PHARM LIMITED

Company Information

for the Period Ended 30 April 2025




Director: Roza Imill Zobedey
Registered office: 17
Rosemary Avenue
London
GBR
N9 8QX
Company Registration Number: 11288434 (England and Wales)

AMROZ PHARM LIMITED

Directors' Report Period Ended 30 April 2025

The directors present their report with the financial statements of the company for the period ended 30 April 2025

Directors

The directors shown below have held office during the whole of the period from 01 May 2024 to 30 April 2025
Roza Imill Zobedey

This report was approved by the board of directors on 7 October 2025
And Signed On Behalf Of The Board By:

Name: Roza Imill Zobedey
Status: Director

AMROZ PHARM LIMITED

Profit and Loss Account

for the Period Ended 30 April 2025


Notes

2025
£

2024
£
Turnover 28,775 20,362
Cost of sales ( 6,571 ) ( 2,265 )
Gross Profit or (Loss) 22,204 18,097
Administrative Expenses ( 8,437 ) ( 8,448 )
Operating Profit or (Loss) 13,767 9,649
Interest Receivable and Similar Income 55 41
Profit or (Loss) Before Tax 13,822 9,690
Tax on Profit ( 2,626 ) ( 1,841 )
Profit or (Loss) for Period 11,196 7,849

The notes form part of these financial statements

AMROZ PHARM LIMITED

Balance sheet

As at 30 April 2025


Notes

2025
£

2024
£
Fixed assets
Total fixed assets: - -
Current assets
Cash at bank and in hand: 6,439 5,106
Total current assets: 6,439 5,106
Creditors: amounts falling due within one year: 4 ( 4,590 ) ( 1,953 )
Net current assets (liabilities): 1,849 3,153
Total assets less current liabilities: 1,849 3,153
Total net assets (liabilities): 1,849 3,153

The notes form part of these financial statements

AMROZ PHARM LIMITED

Balance sheet continued

As at 30 April 2025


Notes

2025
£

2024
£
Capital and reserves
Called up share capital: 1 1
Profit and loss account: 1,848 3,152
Shareholders funds: 1,849 3,153

For the year ending 30 April 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 7 October 2025
And Signed On Behalf Of The Board By:

Name: Roza Imill Zobedey
Status: Director

The notes form part of these financial statements

AMROZ PHARM LIMITED

Notes to the Financial Statements

for the Period Ended 30 April 2025

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

AMROZ PHARM LIMITED

Notes to the Financial Statements

for the Period Ended 30 April 2025

  • 2. Employees


    2025

    2024
    Average number of employees during the period 1 1

AMROZ PHARM LIMITED

Notes to the Financial Statements

for the Period Ended 30 April 2025

  • 3. Off balance sheet disclosure

    No

AMROZ PHARM LIMITED

Notes to the Financial Statements

for the Period Ended 30 April 2025

4.Creditors: amounts falling due within one year note


2025
£

2024
£
Taxation and social security 4,467 1,841
Other creditors 123 112
Total 4,590 1,953